
del Val
Articles
-
Jan 22, 2025 |
link.springer.com | del Val |Josep Maria |Alzheimer’s disease |Universitat de Barcelona
AbstractPlasma tau phosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) have demonstrated high accuracy for Alzheimer’s disease (AD) diagnosis, defined by CSF/PET amyloid beta (Aβ) positivity, but most studies have been performed in research cohorts, limiting their generalizability. We studied plasma p-tau217 and p-tau181 for CSF Aβ status discrimination in a cohort of consecutive patients attending an academic memory clinic in Spain (July 2019–June 2024).
-
Jan 9, 2025 |
dialnet.unirioja.es | del Val |José María Alonso
Ayuda Buscar en la ayuda Buscar en la ayuda
-
Dec 4, 2024 |
burjcdigital.urjc.es | del Val
Date: 2019AbstractEste artículo recupera, por medio de entrevistas en profundidad, la memoria de jóvenes que participaron de diversas escenas musicales y culturas juveniles que emergieron en Madrid y Valencia en los años ochenta.
-
Nov 25, 2024 |
academic.oup.com | Servicio de Cardiología |del Val
Drug-coated balloons (DCB) offer an appealing therapeutic alternative for the treatment of patients with coronary in-stent restenosis (ISR). In-segment late lumen loss, translating into recurrent ISR and the clinical need for target lesion revascularization represent a well-established and thoroughly investigated limitation of DCB in this setting.
-
Aug 14, 2024 |
academic.oup.com | del Val |Isala Hartcentrum |De Luca
To evaluate the individual as well as combined impact of OCT-detected vulnerability features (OCT-VFs) in the prediction of major adverse cardiovascular events (MACE) in non-ischemic lesions in patients with diabetes mellitus (DM). The COMBINE OCT-FFR (NCT02989740) was a prospective, double-blind, international, natural history study that included patients with DM having ≥1 lesions with a fractional flow reserve >0.80, undergoing systematic OCT assessment.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →